Mosenzon, O., Pollack, R. and Raz, I. (2016) Treatment of Type 2 Diabetes: From “Guidelines” to “Position Statements” and Back: Recommendations of the Israel National Diabetes Council. Diabetes Care, 39, S146-S153.
https://doi.org/10.2337/dcS15-3003

has been cited by the following article:

• TITLE: Insulin Glargine 300 Units/mL Effectiveness in Patients with T2DM Uncontrolled by Basal Insulin in Real-Life Settings in the Czech Republic

  AUTHORS: Martin Prázný, Milan Flekač, Petr Jelínek, Jana Mašková

  KEYWORDS: Fasting Plasma Glucose, Glycated Hemoglobin, Hypoglycemia, Insulin Glargine (Gla-300 Units/Ml), Real Life Data, Type 2 Diabetes (T2DM)

  JOURNAL NAME: Journal of Diabetes Mellitus, Vol.10 No.3, June 23, 2020

  ABSTRACT: Introduction: To evaluate the clinical effectiveness of Gla-300 units/mL (Gla-300) in the treatment of patients with type 2 diabetes (T2DM) uncontrolled by basal insulin in real-life clinical settings in the Czech Republic (TOPAZ study). Methods: TOPAZ was a prospective, multi-center, non-interventional, 6-month study. Of the 312 patients screened, 289 were evaluated at month 6. The primary objective was the change of HbA1c after 6 months. The proportion of patients with HbA1c Results: HbA1c decreased significantly after 6 months (mean change 0.9% ± 1.1% DCCT [−9.9 ± 11.6 mmol/mol], p −1.8 ± 3.1 mmol/L) as well as the incidence of hypoglycemia decreased by 49% (p 0.0001) while no weight gain was observed. No significant safety signals were identified. Conclusion: In a real-life setting, switching to Gla-300 in T2DM patients uncontrolled with other basal insulin was associated with improved glycemic control and reduced risk of hypoglycemia without weight gain, while patients’ satisfaction with treatment increased.